Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Palovarotene in Hepatic Impairment
NCT06908954Phase 1Completed
- Sponsor
- Ipsen
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of palovarotene (3 arms), sponsored by Ipsen. Primary endpoints: Maximum observed plasma drug concentration at 96 hours, Unbound fraction of drug in plasma at 96 hours and 5 more. Started Mar 2025; status: completed.
02
Drugs
palovarotene
Beyond the preview
Go deeper on NCT06908954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908954.